Clinical Trials Logo

Filter by:
NCT ID: NCT06151236 Not yet recruiting - Clinical trials for Merkel Cell Carcinoma

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Start date: February 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival

NCT ID: NCT06148051 Recruiting - Cadasil Clinical Trials

AusCADASIL: An Australian Cohort of CADASIL

Start date: November 25, 2023
Phase:
Study type: Observational

The aim of this project is to establish an Australian cohort of patients diagnosed with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). This study will examine the clinical features and longitudinal course of CADASIL. Outcome measures include neuropsychological profile, neuroimaging, genetics, blood biomarkers, and retinal imaging.

NCT ID: NCT06148025 Recruiting - Clinical trials for Vaccine Response Impaired

Antibiotics and Vaccine Immune Responses Study

AVIRS
Start date: November 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

NCT ID: NCT06147921 Not yet recruiting - Healthy Volunteers Clinical Trials

Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants

Start date: December 15, 2023
Phase: Phase 1
Study type: Interventional

Verasone™ is an aqueous suspension of the combination of two marketed drugs to be dosed by sinonasal irrigation in the treatment of Chronic Rhinosinusitis (CRS). This Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of Verasone versus placebo in healthy normal participants and will evaluate the PK profiles of the Verasone active components administered individually vs in combination.

NCT ID: NCT06144840 Not yet recruiting - Clinical trials for Erythropoietic Protoporphyria (EPP)

INcreased Sun Exposure Without Pain In Research Subjects With EPP

INSPIRE
Start date: December 15, 2023
Phase: Phase 3
Study type: Interventional

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

NCT ID: NCT06140758 Active, not recruiting - Caries Clinical Trials

Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model

Start date: July 31, 2023
Phase: N/A
Study type: Interventional

The primary objective is to compare the remineralization and demineralization inhibition potential of early subsurface carious lesions in enamel in situ after rinsing with six different aqueous slurries of toothpaste formulations.

NCT ID: NCT06140745 Completed - Caries Clinical Trials

Evaluation of Dentifrice Formulations to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind In-Situ Clinical Trial

Start date: October 5, 2020
Phase: N/A
Study type: Interventional

To compare the remineralization and demineralization inhibition potential of early subsurface carious lesions in enamel in situ after rinsing with five different aqueous slurries of toothpaste formulations. Percent remineralization (%R), i.e. the % change in ΔZ values relative to ΔZd, will be the primary outcome measure.

NCT ID: NCT06140329 Not yet recruiting - Clinical trials for Autosomal Dominant Optic Atrophy

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Start date: February 2024
Phase:
Study type: Observational

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

NCT ID: NCT06138808 Not yet recruiting - Clinical trials for Epilepsy Intractable

5-SENSE Score Validation Study

Start date: November 2023
Phase:
Study type: Observational

The purpose of this study is to assess how well a new scoring system called the 5-SENSE score can predict where seizures start in the brain using Stereoelectroencephalography (SEEG). The 5-SENSE Score is a 5-point score based on routine presurgical work-up, designed to assist in predicting whether SEEG can identify a focal seizure onset zone, thereby sparing patients the risk of undergoing this invasive diagnostic procedure.

NCT ID: NCT06137807 Not yet recruiting - Clinical trials for Tricuspid Regurgitation

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation Regurgitation (TRICAV)

TRICAV
Start date: January 2024
Phase: N/A
Study type: Interventional

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve implantation system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.